A detailed history of Korea Investment Corp transactions in United Therapeutics Corp stock. As of the latest transaction made, Korea Investment Corp holds 36,989 shares of UTHR stock, worth $13.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
36,989
Previous 17,690 109.1%
Holding current value
$13.3 Million
Previous $5.64 Million 135.23%
% of portfolio
0.03%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$311.04 - $363.55 $6 Million - $7.02 Million
19,299 Added 109.1%
36,989 $13.3 Million
Q2 2024

Aug 13, 2024

BUY
$228.26 - $319.04 $2.52 Million - $3.52 Million
11,022 Added 165.3%
17,690 $5.64 Million
Q1 2024

May 14, 2024

SELL
$210.76 - $249.51 $147,953 - $175,156
-702 Reduced 9.53%
6,668 $1.53 Million
Q4 2023

Feb 13, 2024

SELL
$214.88 - $256.94 $244,318 - $292,140
-1,137 Reduced 13.37%
7,370 $1.62 Million
Q3 2023

Nov 13, 2023

BUY
$211.82 - $248.24 $737,557 - $864,371
3,482 Added 69.29%
8,507 $1.92 Million
Q2 2023

Aug 11, 2023

SELL
$205.19 - $232.99 $1.43 Million - $1.62 Million
-6,965 Reduced 58.09%
5,025 $1.11 Million
Q1 2023

May 12, 2023

BUY
$212.99 - $276.17 $2.55 Million - $3.31 Million
11,990 New
11,990 $2.69 Million
Q3 2018

Nov 13, 2018

SELL
$113.81 - $129.46 $6.97 Million - $7.93 Million
-61,256 Closed
0 $0
Q2 2018

Aug 13, 2018

SELL
$101.14 - $118.31 $283,192 - $331,268
-2,800 Reduced 4.37%
61,256 $0
Q1 2018

May 09, 2018

SELL
$107.21 - $151.94 $1.12 Million - $1.59 Million
-10,444 Reduced 14.02%
64,056 $7.2 Million
Q4 2017

Feb 12, 2018

BUY
$118.58 - $151.28 $2.04 Million - $2.6 Million
17,200 Added 30.02%
74,500 $11 Million
Q3 2017

Oct 25, 2017

BUY
$114.6 - $136.81 $6.57 Million - $7.84 Million
57,300
57,300 $6.72 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Korea Investment Corp Portfolio

Follow Korea Investment Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Korea Investment Corp, based on Form 13F filings with the SEC.

News

Stay updated on Korea Investment Corp with notifications on news.